Early oncology clinical trial design in the era of molecular-targeted agents

Future Oncology

Volumn 6, Issue 8, 2010, Pages 1339-1352

  Brunetto, Andre T ^a   Kristeleit, Rebecca S ^b   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

biomarkers; dose escalation; drug discovery; exploratory end point; molecularly targeted agent; patient selection; Phase I trial; trial design; validation

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG MONITORING; DRUG RESEARCH; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HUMAN; LETHAL DOSE; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; STANDARD; STATISTICAL ANALYSIS; STUDY DESIGN;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 77956326593     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.92     Document Type: Review

References (90)

1. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
2. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719-726 (2002).
3. Demetri GD, von Mehren M, Blanke CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472-480 (2002).
4. Skipper HE: Perspectives in cancer chemotherapy: therapeutic design. Cancer Res. 24, 1295-1302 (1964).
5. Skipper HE, Schabel FM Jr, Wilcox WS: Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother. Rep. 45, 5-28 (1965).
6. Oguri S, Sakakibara T, Mase H et al.: Clinical pharmacokinetics of carboplatin. J. Clin. Pharmacol. 28(3), 208-215 (1988).
7. Speth PA, Linssen PC, Termond EF, Boezeman JB, Wessels HM, Haanen C: In vivo and in vitro pharmacokinetic differences between four structurally closely related anthracyclines in hematopoietic cell subtypes in humans. Drug Metab. Dispos. 17(1), 98-105 (1989).
8. Campone M, Fumoleau P, Delecroix V et al.: Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Ann. Oncol. 12(7), 909-918 (2001).
9. Therasse P, Arbuck SG, Eisenhauer EA et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000).
10. Rixe O, Fojo T: Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin. Cancer Res. 13(24), 7280-7287 (2007).
11. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P: Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J. Natl Cancer Inst. 91(15), 1281-1287 (1999).
12. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A: Translation of innovative designs into Phase I trials. J. Clin. Oncol. 25(31), 4982-4986 (2007).
13. Storer BE: Design and analysis of Phase I clinical trials. Biometrics 45(3), 925-937 (1989).
14. Simon R, Freedman LS: Bayesian design and analysis of two two factorial clinical trials. Biometrics 53(2), 456-464 (1997).
15. Cantarini MV, Macpherson MP, Marshall AL, Robinson AV, Bailey CJ: A Phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (Iressa) in healthy male volunteers. Cancer Chemother. Pharmacol. 56(6), 557-562 (2005).
16. Oken MM, Creech RH, Tormey DC et al.: Toxicity and response criteria of the eastern cooperative oncology group. Am. J. Clin. Oncol. 5(6), 649-655 (1982).
17. Karnofsky DA, Ellison RR, Golbey RB: Selection of patients for evaluation of chemotherapeutic procedures in advanced cancer. Cancer Chemother. Rep. 16, 73-77 (1962).
18. Parulekar WR, Eisenhauer EA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J. Natl Cancer Inst. 96(13), 990-997 (2004).
19. Collins JM, Grieshaber CK, Chabner BA: Pharmacologically guided Phase I clinical trials based upon preclinical drug development. J. Natl Cancer Inst. 82(16), 1321-1326 (1990).
20. O Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for Phase 1 clinical trials in cancer. Biometrics 46(1), 33-48 (1990).
21. Babb J, Rogatko A, Zacks S: Cancer Phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 17(10), 1103-1120 (1998).
22. Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G: New paradigm in dose-finding trials: patient-specific dosing and beyond Phase I. Clin. Cancer Res. 11(15), 5342-5346 (2005).
23. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC: Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol. 19(1), 265-272 (2001).
24. Cannistra SA: Challenges and pitfalls of combining targeted agents in Phase I studies. J. Clin. Oncol. 26(22), 3665-3667 (2008).
25. Sleijfer S, Wiemer E: Dose selection in Phase I studies: why we should always go for the top. J. Clin. Oncol. 26(10), 1576-1578 (2008).
26. Bria E, DI Maio M, Carlini P et al.: Targeting targeted agents: open issues for clinical trial design. J. Exp. Clin. Cancer Res. 28, 66 (2009).
27. Hunsberger S, Rubinstein LV, Dancey J, Korn EL: Dose escalation trial designs based on a molecularly targeted endpoint. Stat. Med. 24(14), 2171-2181 (2005).
28. Gripp S, Moeller S, Bolke E et al.: Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J. Clin. Oncol. 25(22), 3313-3320 (2007).
29. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S: Clinical outcome and prognostic factors for patients treated within the context of a Phase I study: the Royal Marsden Hospital experience. Br. J. Cancer 98(6), 1029-1033 (2008).
30. Arkenau HT, Barriuso J, Olmos D et al.: Prospective validation of a prognostic score to improve patient selection for oncology Phase I trials. J. Clin. Oncol. 27(16), 2692-2696 (2009).
31. Wheler J, Tsimberidou AM, Hong D et al.: Survival of patients in a Phase I clinic: the M. D. Anderson cancer center experience. Cancer 115(5), 1091-1099 (2009).
32. Bachelot T, Ray-Coquard I, Catimel G et al.: Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in Phase I clinical trials. Ann. Oncol. 11(2), 151-156 (2000).
33. Penel N, Vanseymortier M, Bonneterre ME et al.: Prognostic factors among cancer patients with good performance status screened for Phase I trials. Invest. New Drugs 26(1), 53-58 (2008).
34. Italiano A, Massard C, Bahleda R et al.: Treatment outcome and survival in participants of Phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann. Oncol. 19(4), 787-792 (2008).
35. Nurgat ZA, Craig W, Campbell NC, Bissett JD, Cassidy J, Nicolson MC: Patient motivations surrounding participation in Phase I and Phase I clinical trials of cancer chemotherapy. Br. J. Cancer 92(6), 1001-1005 (2005).
36. Cheng JD, Hitt J, Koczwara B et al.: Impact of quality of life on patient expectations regarding Phase I clinical trials. J. Clin. Oncol. 18(2), 421-428 (2000).
37. Markman M: The ethical dilemma of Phase I clinical trials. CA Cancer J. Clin. 36(6), 367-369 (1986).
38. Daugherty C, Ratain MJ, Grochowski E et al.: Perceptions of cancer patients and their physicians involved in Phase I trials. J. Clin. Oncol. 13(5), 1062-1072 (1995).
39. Meropol NJ, Weinfurt KP, Burnett CB et al.: Perceptions of patients and physicians regarding Phase I cancer clinical trials: implications for physician-patient communication. J. Clin. Oncol. 21(13), 2589-2596 (2003).
40. Saunders C: The evolution of palliative care. Patient Educ. Couns. 41(1), 7-13 (2000).
41. Hearn J, Higginson IJ: Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Palliat. Med. 12(5), 317-332 (1998).
42. Higginson I, Wade A, Mccarthy M: Palliative care: views of patients and their families. BMJ 301(6746), 277-281 (1990).
43. Fox E, Curt GA, Balis FM: Clinical trial design for target-based therapy. Oncologist 7(5), 401-409 (2002).
44. Stadler WM, Ratain MJ: Development of target-based antineoplastic agents. Invest. New Drugs 18(1), 7-16 (2000).
45. Dowlati A, Manda S, Gibbons J, Remick SC, Patrick L, Fu P: Multi-institutional Phase I trials of anticancer agents. J. Clin. Oncol. 26(12), 1926-1931 (2008).
46. Postel-Vinay S, Arkenau HT, Olmos D et al.: Clinical benefit in phase-I trials of novel molecularly targeted agents: does dose matter? Br. J. Cancer 100(9), 1373-1378 (2009).
47. Park JW, Kerbel RS, Kelloff GJ et al.: Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin. Cancer Res. 10(11), 3885-3896 (2004).
48. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
49. Press MF, Bernstein L, Thomas PA et al.: Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15(8), 2894-2904 (1997).
50. Rustin GJ, Bast RC Jr, Kelloff GJ et al.: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 10(11), 3919-3926 (2004).
51. de Bono JS, Attard G, Adjei A et al.: Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin. Cancer Res. 13(12), 3611-3616 (2007).
52. Prat A, Parera M, Adamo B et al.: Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (eoc) with a low-level increase of serum CA-125 levels. Ann. Oncol. 20(2), 294-297 (2009).
53. Jackson A, O Connor JP, Parker GJ, Jayson GC: Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin. Cancer Res. 13(12), 3449-3459 (2007).
54. Clarke PA, Hostein I, Banerji U et al.: Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17- demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19(36), 4125-4133 (2000).
55. O Donnell A, Faivre S, Burris HA 3rd et al.: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1588-1595 (2008).
56. Baselga J, Rischin D, Ranson M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20(21), 4292-4302 (2002).
57. Albanell J, Rojo F, Averbuch S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20(1), 110-124 (2002)
58. Jost M, Kari C, Rodeck U: The EGF receptor - an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 10(7), 505-510 (2000).
59. Malik SN, Siu LL, Rowinsky EK et al.: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin. Cancer Res. 9(7), 2478-2486 (2003).
60. Workman P: Using biomarkers in drug development. Clin. Adv. Hematol. Oncol. 4(10), 736-739 (2006).
61. Helft PR, Daugherty CK: Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J. Clin. Oncol. 24(30), 4793-4795 (2006).
62. Agulnik M, Oza AM, Pond GR, Siu LL: Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J. Clin. Oncol. 24(30), 4801-4807 (2006).
63. Felip E, Rojo F, Reck M et al.: A Phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin. Cancer Res. 14(12), 3867-3874 (2008).
64. Morgan B, Thomas AL, Drevs J et al.: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol. 21(21), 3955-3964 (2003).
65. Drevs J, Siegert P, Medinger M et al.: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25(21), 3045-3054 (2007).
66. Morse Dl, Galons JP, Payne CM et al.: MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed. 20(6), 602-614 (2007).
67. Hein PA, Kremser C, Judmaier W et al.: Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur. J. Radiol. 45(3), 214-222 (2003).
68. Moffat BA, Chenevert TL, Lawrence TS et al.: Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc. Natl Acad. Sci. USA 102(15), 5524-5529 (2005).
69. Theilmann RJ, Borders R, Trouard TP et al.: Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6(6), 831-837 (2004).
70. Koh DM, Blackledge M, Collins DJ et al.: Reproducibility and changes in the apparent diffusion coefficients of solid tumors treated with combretastatin A4 phosphate and bevacizumab in a two-centre Phase I clinical trial. Eur. Radiol. 19(11), 2728-2738 (2009).
71. Bos R, van Der Hoeven JJ, van Der Wall E et al.: Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol. 20(2), 379-387 (2002).
72. Kunkel M, Reichert TE, Benz P et al.: Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97(4), 1015-1024 (2003).
73. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K: Evaluation of 18F-2- deoxy-2-fluoro-d-glucose positron emission tomography for gastric cancer. World J. Surg. 28(3), 247-253 (2004).
74. Stroobants S, Goeminne J, Seegers M et al.: 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 39(14), 2012-2020 (2003).
75. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ: FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 35(2), 179-187 (2002).
76. De Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ: Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 110(8), 1654-1664 (2007).
77. Dimitrakopoulou-Strauss A, Strauss LG: PET imaging of prostate cancer with 11C-acetate. J. Nucl. Med. 44(4), 556-558 (2003).
78. Leach MO, Brindle KM, Evelhoch JL et al.: The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br. J. Cancer 92(9), 1599-1610 (2005).
79. Allard WJ, Matera J, Miller MC et al.: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10(20), 6897-6904 (2004).
80. Cristofanilli M, Budd GT, Ellis MJ et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
81. de Bono JS, Scher HI, Montgomery RB et al.: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302-6309 (2008).
82. Cohen SJ, Punt CJ, Iannotti N et al.: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(19), 3213-3221 (2008).
83. Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA: Trends in the use and role of biomarkers in Phase I oncology trials. Clin. Cancer Res. 13(22 Pt 1), 6719-6726 (2007).
84. Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845-856 (2005).
85. Workman P, Aboagye EO, Chung YL et al.: Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl Cancer Inst. 98(9), 580-598 (2006).
86. Farmer H, Mccabe N, Lord CJ et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005).
87. Fong PC, Boss DS, Yap TA et al.: Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009)
88. Weberpals JI, Clark-Knowles KV, Vanderhyden BC: Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J. Clin. Oncol. 26(19), 3259-3267 (2008).
89. Thomas RK, Baker AC, Debiasi RM et al.: High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39(3), 347-351 (2007).
90. Hennessy BT, Gonzalez-Angulo AM, Carey MS, Mills GB: A systems approach to analysis of molecular complexity in breast cancer. Clin. Cancer Res. 15(2), 417-419 (2009)